Daily Stock Analysis, CALA, Calithera Biosciences Inc, priceseries

Calithera Biosciences Inc. Daily Stock Analysis
Stock Information
Open
3.90
Close
4.07
High
4.11
Low
3.71
Previous Close
3.86
Daily Price Gain
0.21
YTD High
6.90
YTD High Date
Apr 2, 2019
YTD Low
2.45
YTD Low Date
Oct 9, 2019
YTD Price Change
-0.16
YTD Gain
-3.78%
52 Week High
6.90
52 Week High Date
Apr 2, 2019
52 Week Low
2.45
52 Week Low Date
Oct 9, 2019
52 Week Price Change
-0.82
52 Week Gain
-16.77%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 3. 2017
3.60
Jan 19. 2017
4.26
11 Trading Days
18.45%
Link
LONG
Feb 24. 2017
8.95
Mar 17. 2017
12.46
15 Trading Days
39.19%
Link
LONG
May 9. 2017
11.30
May 31. 2017
15.55
15 Trading Days
37.62%
Link
LONG
Jul 3. 2017
15.75
Jul 17. 2017
17.95
9 Trading Days
13.95%
Link
LONG
Oct 4. 2017
15.85
Oct 19. 2017
17.24
11 Trading Days
8.78%
Link
LONG
Aug 24. 2018
4.75
Sep 6. 2018
5.02
8 Trading Days
5.64%
Link
LONG
Feb 8. 2019
4.86
Mar 5. 2019
5.62
16 Trading Days
15.57%
Link
LONG
Mar 8. 2019
5.75
Mar 25. 2019
6.40
11 Trading Days
11.34%
Link
LONG
Oct 31. 2019
2.88
Nov 11. 2019
3.16
7 Trading Days
9.86%
Link
Company Information
Stock Symbol
CALA
Exchange
NasdaqGS
Company URL
http://www.calithera.com
Company Phone
650-870-1000
CEO
Susan M. Molineaux
Headquarters
California
Business Address
343 OYSTER POINT BLVD #200, SOUTH SAN FRANCISCO, CA 94080
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001496671
About

Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company, which focuses on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. The company was founded by James A. Wells and Susan M. Molineaux on March 9, 2010 and is headquartered in South San Francisco, CA.

Description

Calithera Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate includes CB-839, an inhibitor of glutaminase, which is in three Phase I clinical trials for the treatment of patients with solid tumors, leukemias, lymphomas, and multiple myeloma. The company has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare; and license and research agreement with High Point Pharmaceuticals, LLC and TransTech Pharma LLC to develop and commercialize hexokinase II inhibitors. In addition, it has clinical trial collaboration with Bristol-Myers Squibb Company to evaluate Opdivo (nivolumab) in combination with CB-839 in clear cell renal cell carcinoma. The company has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of CB-1158, a small molecule arginase inhibitor for the treatment of hematology and oncology. Calithera Biosciences, Inc. was founded in 2010 and is headquartered in South San Francisco, California.